MEDS DataMeds AI, Inc.
Wholesale-Drugs, Proprietaries & Druggists' Sundries · Nasdaq · SEC CIK 2030763 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-77.5%
TTM net income YoY44.2%
TTM EPS YoY187.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin-92.1%
Operating margin-548.1%
Net margin-564.8%
FCF margin—
EBITDA margin-523.7%
Returns
ROE-1,706.7%
ROA-94.8%
ROIC (approx.)-153.4%
Asset turnover0.17x
Leverage & solvency
Liabilities / assets99.6%
Debt / equity—
Current ratio0.14x
Interest coverage-6.22x
Cash quality & payout
Operating cash flow / net income0.36x
Accruals ratio-60.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $23.34M | $18.13M |
| Cost of revenue | $29.76M | $16.36M |
| Gross profit | -$6.43M | $1.77M |
| SG&A expense | $70.33M | $6.80M |
| Operating income | -$93.75M | -$6.15M |
| Interest expense | $4.58M | $831,467 |
| Pretax income | -$101.27M | -$6.86M |
| Net income | -$101.27M | -$6.86M |
| EBITDA | -$90.54M | -$5.03M |
| EPS (basic) | -1.43 | -0.15 |
| EPS (diluted) | -1.43 | -0.15 |
| Weighted avg. shares (diluted) | 70.99M | 47.25M |
| Balance sheet | ||
| Cash & equivalents | $42,571 | $1.03M |
| Receivables | $1.14M | — |
| Inventory | $1.64M | $9.52M |
| Current assets | $2.82M | $15.17M |
| PP&E, net | $229,376 | $388,180 |
| Goodwill | $14.19M | $16.22M |
| Intangibles | $2.50M | $1.62M |
| Total assets | $30.46M | $57.33M |
| Current liabilities | $29.78M | $38.05M |
| Short-term debt | $10.89M | $11.93M |
| Long-term debt | $12.60M | $11.46M |
| Total debt | $23.49M | $23.38M |
| Total liabilities | $42.91M | $50.60M |
| Shareholders' equity | -$12.45M | $6.73M |
| Net debt | $23.44M | $22.35M |
| Shares outstanding | 2.03M | 51.06M |
| Cash flow statement | ||
| Operating cash flow | -$10.86M | -$1.22M |
| Investing cash flow | -$881,526 | $469,072 |
| Financing cash flow | $10.75M | $1.78M |
| Depreciation & amortization | $3.21M | $1.11M |
| Stock-based compensation | $54.79M | $1.08M |
Free plan shows the latest 2 periods; Pro shows all 3 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.